Puma Biotech Beats Q1 Estimates but Structural Risks Persist

What happened

Puma Biotechnology reported a Q1 2026 loss of $0.04 per share, narrower than the consensus estimate of -$0.13 and down from a profit of $0.10 a year ago. Revenue beat expectations, though the company continues to face headwinds from depressed China royalties and rising gross-to-net deductions. The earnings beat provides near-term support, but the underlying business relies on stable NERLYNX sales and a royalty recovery that has yet to materialize. Management's outlook for 2026 will be critical in assessing whether the revenue beat translates into sustained cash generation. The DeepValue report maintains a WAIT stance, noting that the stock at $6.65 already prices in modest growth and pipeline optionality, leaving limited upside without clearer evidence of durability.

Implication

The Q1 beat provides a temporary cushion, but the structural issues highlighted in the DeepValue report—royalty volatility, gross-to-net pressure, and single-product dependence—remain unresolved. Investors should not chase; the stock trades near the report's base case value of $6.50 with limited margin of safety. Key catalysts are 2026 guidance and H1 alisertib data. The risk-reward skew suggests patience.

Thesis delta

The Q1 beat modestly improves near-term sentiment but does not alter the fundamental risk profile. Royalty and gross-to-net trends remain concerning. The WAIT rating is unchanged; the report's trigger points for increasing exposure (2026 guidance above $205M NERLYNX revenue, royalty recovery) are not yet met.